Author details

Full Name

Mark A Tomai

Affiliation

ORCID

Career Start Year

1986

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36454813	Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later.	Sci Transl Med	2023
37553348	Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques.	Nat Commun	2023
36963999	Preclinical evaluation of immunogenicity, efficacy and safety of a recombinant plant-based SARS-CoV-2 RBD vaccine formulated with 3M-052-Alum adjuvant.		2023
35087093	A molecular atlas of innate immunity to adjuvanted and live attenuated vaccines, in mice.	Nat Commun	2022
35572573	Early Post-Vaccination Gene Signatures Correlate With the Magnitude and Function of Vaccine-Induced HIV Envelope-Specific Plasma Antibodies in Infant Rhesus Macaques.	Front Immunol	2022
36274085	Breadth of SARS-CoV-2 neutralization and protection induced by a nanoparticle vaccine.	Nat Commun	2022
36070369	Stabilized HIV-1 envelope immunization induces neutralizing antibodies to the CD4bs and protects macaques against mucosal infection.	Science Translational Medicine	2022
37854093	Live-Attenuated VEEV Vaccine Delivered by iDNA Using Microneedles Is Immunogenic in Rabbits.		2022
35118474	Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine.	bioRxiv	2022
34972105	Different adjuvanted pediatric HIV envelope vaccines induced distinct plasma antibody responses despite similar B cell receptor repertoires in infant rhesus macaques.	PLoS One	2021
34131024	SARS-CoV-2 vaccines elicit durable immune responses in infant rhesus macaques.	Sci Immunol	2021
33971664	Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses.	Nature	2021
34117252	SARS-CoV-2 RBD trimer protein adjuvanted with Alum-3M-052 protects from SARS-CoV-2 infection and immune pathology in the lung.	Nat Commun	2021
33851156	SARS-CoV-2 Vaccines Elicit Durable Immune Responses in Infant Rhesus Macaques.	bioRxiv	2021
33619494	SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeys.	bioRxiv	2021
34266981	A yeast expressed RBD-based SARS-CoV-2 vaccine formulated with 3M-052-alum adjuvant promotes protective efficacy in non-human primates.	Sci Immunol	2021
34248966	Optimizing a Multi-Component Intranasal <i>Entamoeba Histolytica</i> Vaccine Formulation Using a Design of Experiments Strategy.	Front Immunol	2021
34795290	Development of COVID-19 vaccine using a dual Toll-like receptor ligand liposome adjuvant.	NPJ Vaccines	2021
33038865	New horizons in adjuvants for vaccine development.	Curr Opin Immunol	2020
32393800	T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers.	Nat Med	2020
31511088	Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies.	Journal for ImmunoTherapy of Cancer	2019
31845070	Coated microneedles for transdermal delivery of a potent pharmaceutical peptide.	Biomedical Microdevices	2019
31806786	Targeted selection of HIV-specific antibody mutations by engineering B cell maturation.	Science	2019
29900011	Adjuvant composition and delivery route shape immune response quality and protective efficacy of a recombinant vaccine for <i>Entamoeba histolytica</i>.	NPJ Vaccines	2018
30089691	Adjuvant-Dependent Enhancement of HIV Env-Specific Antibody Responses in Infant Rhesus Macaques.	J Virol	2018
28089548	Nanoformulation of synergistic TLR ligands to enhance vaccination against Entamoeba histolytica.	Vaccine	2017
28429728	A Formulated TLR7/8 Agonist is a Flexible, Highly Potent and Effective Adjuvant for Pandemic Influenza Vaccines.	Scientific Reports	2017
28352660	TLR7/8 adjuvant overcomes newborn hyporesponsiveness to pneumococcal conjugate vaccine at birth.	JCI Insight	2017
27847326	Adsorption of a synthetic TLR7/8 ligand to aluminum oxyhydroxide for enhanced vaccine adjuvant activity: A formulation approach.	J Control Release	2016
25609199	Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.	Oncotarget	2015
23885825	The use of Toll-like receptor 7/8 agonists as vaccine adjuvants.	Expert Review of Vaccines	2013
22521247	Imidazoquinoline Toll-like receptor 8 agonists activate human newborn monocytes and dendritic cells through adenosine-refractory and caspase-1-dependent pathways.	Journal of Allergy and Clinical Immunology	2012
21506636	TLR-7 and -8 agonists as vaccine adjuvants.	Expert Review of Vaccines	2011
20519933	Potentiation of the anti-tumor effects of imidazoquinoline immune response modifiers by cyclophosphamide.	Cancer Biology and Therapy	2010
18791716	NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model.	Cancer Immunology, Immunotherapy	2009
18389099	The antiviral activity of Toll-like receptor 7 and 7/8 agonists.	Drug News and Perspectives	2008
18439103	TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.	Journal of Interferon and Cytokine Research	2008
18334250	Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands.	Cellular Immunology	2007
17475848	Sensitization to TLR7 agonist in IFN-beta-preactivated dendritic cells.	Journal of Immunology	2007
17931162	Resiquimod and other immune response modifiers as vaccine adjuvants.	Expert Review of Vaccines	2007
16959331	Administration of a dual toll-like receptor 7 and toll-like receptor 8 agonist protects against influenza in rats.	Antiviral Research	2007
16728430	Distinct indirect pathways govern human NK-cell activation by TLR-7 and TLR-8 agonists.	International Immunology	2006
16341037	Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells.	Leukemia	2006
16439962	Topical imiquimod treatment prevents UV-light induced loss of contact hypersensitivity and immune tolerance.	Journal of Investigative Dermatology	2006
15887957	Synthesis and structure-activity-relationships of 1H-imidazo[4,5-c]quinolines that induce interferon production.	J Med Chem	2005
15661881	Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8.	Journal of Immunology	2005
14708627	Topically applied imiquimod inhibits vascular tumor growth in vivo.	Journal of Investigative Dermatology	2003
12470615	Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.	Cellular Immunology	2002
11962724	Immunomodulation as a treatment strategy for genital herpes: review of the evidence.	International Immunopharmacology	2002
11237799	Daily or weekly therapy with resiquimod (R-848) reduces genital recurrences in herpes simplex virus-infected guinea pigs during and after treatment.	Journal of Infectious Diseases	2001